9-29
Kodiak Sciences shares jump 183% after Zenkuda wet AMD trial succeeds, setting up filing against Regeneron’s Eylea
Kodiak Sciences said its wet age-related macular degeneration drug candidate Zenkuda met its clinical trial goals, clearing the way for a regulatory submission. The company said it plans to file the treatment for approval. The update sent Kodiak’s shares up 183% in a single session. Zenkuda is positioned to compete directly with Regeneron’s blockbuster Eylea, drawing heightened investor attention.
9-29